Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) has promoted Carol Lizak to the role of chief financial officer. This decision reflects her significant contributions in finance and strategic planning since joining the company in May 2019. Lizak brings over 20 years of experience in financial roles across various companies, enhancing Jaguar's transition from an R&D focus to a commercial-stage entity. Jaguar specializes in plant-based, non-opioid medicines for gastrointestinal issues and is known for its Mytesi® product, which is FDA-approved for treating noninfectious diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (NASDAQ:JAGX) announced employee inducement grants on March 26, 2021, allocating nonstatutory stock options totaling 2,000 to 35,000 shares to five new employees. The exercise price is set at $1.84 per share, reflecting the March 26 closing price. Vesting occurs over three years, with the first 25% vesting nine months post-hire. Grants were made to attract talent as per NASDAQ rules. Jaguar develops plant-based medicines focused on gastrointestinal conditions, notably offering Mytesi, an FDA-approved product for HIV/AIDS patients.
Jaguar Health reported strong financial results for 2020, with Mytesi net sales rising 64% to approximately $9.3 million and gross sales increasing 148% to around $20.4 million. Despite a 7% decline in total Mytesi unit sales volume, the company saw a 12% reduction in net loss, totaling $33.8 million. Operating expenses grew by 4% year-over-year, primarily due to a rise in inducement expenses. Jaguar's focus on R&D remains evident with expenses of $6.4 million, reflecting ongoing development of Mytesi indications.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced its support for the selection of the investment bank and nominated advisor for the proposed merger of the Dragon SPAC with its Italian subsidiary, Napo EU. This merger is anticipated to list on AIM Italia. Additionally, Jaguar's subsidiary conducted a meeting with the EU regulatory authority regarding crofelemer for COVID-related diarrhea, indicating the presence of unmet medical needs in this domain. Regulatory approval would allow for a conditional marketing authorization, utilizing safety data from Napo's approved US NDA.
Jaguar Health has incorporated its subsidiary, Napo EU, in Italy to combat inflammatory diarrhea linked to long-hauler syndrome post-COVID-19, primarily in Europe. The subsidiary is the target of a forthcoming merger with the Dragon SPAC, expected to list on AIM Italia. CEO Lisa Conte announced the search for key management roles and ongoing regulatory efforts to gain conditional marketing authorization from the European Medicines Agency (EMA).
Jaguar Health has signed a definitive agreement for a $5 million non-dilutive royalty financing transaction, related to future sales of crofelemer (Mytesi) for a COVID-related indication targeting long-hauler patients. This financing will support regulatory activities and the development pipeline for crofelemer. The company is also identifying key opinion leaders in the US and Europe to address symptoms affecting COVID-19 survivors. With no royalty payments due for 36 months, Jaguar aims to leverage this opportunity to explore the growing market of long-hauler syndrome.
Jaguar Health has signed a binding agreement for a $5 million non-dilutive royalty financing to support the development of crofelemer for a COVID-related indication in long-hauler patients. This financing adds to previous transactions totaling $12 million since late 2020. The company aims for accelerated conditional approval of crofelemer in the EU. The Dragon SPAC, targeting AIM Italia, will focus on Napo EU's projects, providing additional updates expected next week. Mytesi, approved by the FDA, serves as an anti-diarrheal for adults with HIV/AIDS.
Jaguar Health has launched the Napo EU website in Italy, providing resources on post-COVID-19 long-hauler syndrome, including gastrointestinal symptoms like diarrhea. The site links to relevant studies and aims to explore the conditional marketing authorization of crofelemer for inflammatory diarrhea in long-hauler patients in Europe. In a recent study, 30% of COVID-19 survivors reported ongoing symptoms, highlighting the potential market for Jaguar's Mytesi product. The company continues to advocate for its plant-based therapies targeting GI distress.
Jaguar Health (NASDAQ:JAGX) is advancing plans for an exclusive relationship with the Dragon SPAC, targeting the listing of its subsidiary, Napo EU, on AIM Italia. An MOU has been signed with Josh Mailman, the lead sponsor of Dragon SPAC, which will negotiate the merger with Napo EU. The company is also seeking conditional marketing authorization in Europe for crofelemer to treat inflammatory diarrhea, particularly among 'long-hauler' COVID-19 patients. A meeting with European regulatory authorities is scheduled for March 2021.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
